Adial Pharmaceuticals Inc (NASDAQ: ADIL) closed the day trading at $2.24 down -14.18% from the previous closing price of $2.61. On the day, 653177 shares were traded. ADIL stock price reached its highest trading level at $2.8699 during the session, while it also had its lowest trading level at $2.2900.
Ratios:
For a better understanding of ADIL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on October 30, 2018, initiated with a Buy rating and assigned the stock a target price of $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 29 ’23 when Schuyler Kevin bought 700 shares for $2.74 per share. The transaction valued at 1,918 led to the insider holds 700 shares of the business.
Stock Price History:
Over the past 52 weeks, ADIL has reached a high of $14.00, while it has fallen to a 52-week low of $0.76.
Shares Statistics:
A total of 4.05M shares are outstanding, with a floating share count of 3.67M. Insiders hold about 9.50% of the company’s shares, while institutions hold 6.55% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.33, while EPS last year was -$2.75. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.33 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.36 and -$2.62 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.59, with 2 analysts recommending between -$1.27 and -$1.92.
